{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:22:33Z","timestamp":1794068553149,"version":"4.8.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>HIF\u2013prolyl hydroxylase inhibitors (HIF-PHIs) are oral alternatives to erythropoiesis-stimulating agents (ESAs) for anemia in chronic kidney disease (CKD). We performed a network meta-analysis comparing six HIF-PHIs (roxadustat, daprodustat, vadadustat, molidustat, enarodustat, desidustat) versus ESAs or placebo across hemoglobin efficacy, iron indices, and adverse events, with prespecified subgroup analyses by dialysis status. Forty-five randomized trials enrolling over 32,000 participants were analyzed using both frequentist and Bayesian frameworks with inconsistency checks. Outcomes included hemoglobin, ferritin, hepcidin, serum iron, total iron-binding capacity, and transferrin saturation; VEGF and lipid endpoints were not synthesized due to sparse, heterogeneous reporting. Across analyses, roxadustat and daprodustat increased hemoglobin more than ESA or placebo overall. Roxadustat tended to rank highest for hemoglobin, particularly in non-dialysis populations, whereas daprodustat showed advantages among dialysis-dependent patients and was associated with greater improvements in iron mobilization (lower hepcidin and ferritin, higher transferrin saturation). Estimates for desidustat and vadadustat were favorable but less precise, while evidence for enarodustat and molidustat was limited. Safety appeared class-neutral in aggregate; however, agent-specific patterns emerged\u2014roxadustat showed higher rates of vascular occlusive events in some trials, daprodustat more gastrointestinal events, and molidustat a lower risk of hyperkalemia. Because SUCRA ranks reflect probability rather than effect magnitude, rankings were interpreted alongside absolute effects and study design. In sum, HIF-PHIs are not interchangeable; efficacy and safety vary by agent and dialysis status. Choice of therapy should consider inflammatory burden, iron handling, and adherence context. Head-to-head trials and real-world studies are needed to validate comparative findings and guide personalized use.<\/jats:p>","DOI":"10.1186\/s12882-025-04561-x","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:33:21Z","timestamp":1763138001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD: effects on hemoglobin, iron markers, and adverse clinical outcomes"],"prefix":"10.1186","volume":"26","author":[{"given":"Hasti","family":"Nasiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Mirmazhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Mirzakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parham","family":"Asgarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Gholibeigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Ghandali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Talebi","family":"Moghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atieh","family":"Makhlough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"6","key":"4561_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.nefro.2024.03.002","volume":"44","author":"Navarro Gonz\u00e1lez","year":"2024","unstructured":"Navarro Gonz\u00e1lez, Ortiz A, Cebri\u00e1n Cuenca, Moreno Bar\u00f3n, L S, Pimentel B, et al. Projection of the clinical and economic burden of chronic kidney disease between 2022 and 2027 in Spain: results of the inside CKD project. Nefrolog\u00eda (English Edition). 2024;44(6):807\u201317.","journal-title":"Nefrolog\u00eda"},{"issue":"7","key":"4561_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20(7):473\u201385.","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"4561_CR3","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631\u201334.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"4561_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.nefro.2020.11.003","volume":"41","author":"A Cases","year":"2021","unstructured":"Cases A, Puchades MJ, de Sequera P, Quiroga B, Martin-Rodriguez L, Gorriz JL, et al. Iron replacement therapy in the management of anaemia in non-dialysis chronic kidney disease patients: perspective of the Spanish nephrology society anaemia group. Nefrolog\u00eda (English Edition). 2021;41(2):123\u201336.","journal-title":"Nefrolog\u00eda"},{"key":"4561_CR5","doi-asserted-by":"crossref","unstructured":"Badura K, Janc J, W\u0105sik J, Gnitecki S, Skwira S, M\u0142ynarska E, et al. Anemia of chronic kidney disease-A narrative review of its pathophysiology. Diagnosis Manag Biomedicines. 2024;12(6).","DOI":"10.3390\/biomedicines12061191"},{"key":"4561_CR6","first-page":"195","volume":"2","author":"A Hayat","year":"2008","unstructured":"Hayat A, Haria D, Salifu MO. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. Patient Prefer Adherence. 2008;2:195\u2013200.","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"4561_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","volume":"71","author":"S Fishbane","year":"2018","unstructured":"Fishbane S, Spinowitz B. Update on anemia in ESRD and Earlier stages of CKD: core curriculum 2018. Am J Kidney Dis. 2018;71(3):423\u201335.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"4561_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000521162","volume":"8","author":"HHL Wu","year":"2022","unstructured":"Wu HHL, Chinnadurai R. Erythropoietin-stimulating agent Hyporesponsiveness in patients living with chronic kidney disease. Kidney Dis (Basel). 2022;8(2):103\u201314.","journal-title":"Kidney Dis (basel)"},{"issue":"1","key":"4561_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000510587","volume":"7","author":"X Hu","year":"2021","unstructured":"Hu X, Xie J, Chen N. Hypoxia-inducible Factor-proline hydroxylase inhibitor in the treatment of renal anemia. Kidney Dis (Basel). 2021;7(1):1\u20139.","journal-title":"Kidney Dis (Basel)"},{"key":"4561_CR10","doi-asserted-by":"crossref","unstructured":"Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl (2011). 2021;11(1):8\u201325.","DOI":"10.1016\/j.kisu.2020.12.002"},{"issue":"1","key":"4561_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000527835","volume":"9","author":"J Li","year":"2023","unstructured":"Li J, Haase VH, Hao CM. Updates on hypoxia-inducible factor prolyl hydroxylase inhibitors in the treatment of renal anemia. Kidney Dis (Basel). 2023;9(1):1\u201311.","journal-title":"Kidney Dis (Basel)"},{"issue":"11","key":"4561_CR12","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1681\/ASN.2022040413","volume":"33","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, Del Vecchio L. Hypoxia-inducible Factor-prolyl hydroxyl Domain inhibitors: from theoretical superiority to clinical noninferiority compared with current ESAs? J Am Soc Nephrol. 2022;33(11):1966\u201379.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4561_CR13","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.18632\/aging.204611","volume":"15","author":"J Chen","year":"2023","unstructured":"Chen J, Shou X, Xu Y, Jin L, Zhu C, Ye X, et al. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease. Aging (Albany NY). 2023;15(6):2237\u201374.","journal-title":"Aging (albany NY)"},{"key":"4561_CR14","doi-asserted-by":"crossref","unstructured":"Fadlalmola H, Al-Sayaghi K, Al-Hebshi A, Aljohani M, Albalawi M, Kashari O, et al. Efficacy of different doses of Daprodustat for anemic non-dialysis patients with chronic kidney disease: a systematic review and network meta-analysis. J Clin Med. 2022;11(10).","DOI":"10.3390\/jcm11102722"},{"key":"4561_CR15","doi-asserted-by":"publisher","first-page":"1406588","DOI":"10.3389\/fphar.2024.1406588","volume":"15","author":"S Ren","year":"2024","unstructured":"Ren S, Zhao Y, Wu J, Ren S, Feng Y. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis. Front Pharmacol. 2024;15:1406588.","journal-title":"Front Pharmacol"},{"issue":"5","key":"4561_CR16","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/ckj\/sfac271","volume":"16","author":"K Takkavatakarn","year":"2023","unstructured":"Takkavatakarn K, Thammathiwat T, Phannajit J, Katavetin P, Praditpornsilpa K, Eiam-Ong S, et al. The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic review and meta-analysis. Clin Kidney J. 2023;16(5):845\u201358.","journal-title":"Clin Kidney J"},{"issue":"3","key":"4561_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/stats8030072","volume":"8","author":"V Papadopoulos","year":"2025","unstructured":"Papadopoulos V. On the appropriateness of fixed correlation assumptions in repeated-measures Meta-analysis: A monte carlo assessment. Stats. 2025;8(3):72.","journal-title":"Stats"},{"key":"4561_CR18","unstructured":"Front Matter. Cochrane Handbook for Systematic Reviews of Interventions. 2019. i-xxviii."},{"issue":"10","key":"4561_CR19","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","volume":"30","author":"A Besarab","year":"2015","unstructured":"Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transpl. 2015;30(10):1665\u201373.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"4561_CR20","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","volume":"67","author":"R Provenzano","year":"2016","unstructured":"Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67(6):912\u201324.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"4561_CR21","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","volume":"32","author":"N Chen","year":"2017","unstructured":"Chen N, Qian J, Chen J, Yu X, Mei C, Hao C, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transpl. 2017;32(8):1373\u201386.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"4561_CR22","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1007\/s12325-019-00943-4","volume":"36","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Iwasaki M, Otsuka T, Reusch M, Misumi T. Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Adv Ther. 2019;36(6):1438\u201354.","journal-title":"Adv Ther"},{"issue":"11","key":"4561_CR23","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381(11):1001\u201310.","journal-title":"N Engl J Med"},{"issue":"11","key":"4561_CR24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, et al. Roxadustat treatment for Anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011\u201322.","journal-title":"N Engl J Med"},{"issue":"7","key":"4561_CR25","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2019060623","volume":"31","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M. Phase 3, randomized, double-blind, active-comparator (Darbepoetin Alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. J Am Soc Nephrol. 2020;31(7):1628\u201339.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"4561_CR26","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ekir.2021.04.003","volume":"6","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Iwasaki M, Otsuka T, Yamaguchi Y, Reusch M. Phase 3 study of Roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney Int Rep. 2021;6(7):1810\u201328.","journal-title":"Kidney Int Rep"},{"issue":"9","key":"4561_CR27","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","volume":"36","author":"J Barratt","year":"2021","unstructured":"Barratt J, Andric B, Tataradze A, Sch\u00f6mig M, Reusch M, Valluri U, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transpl. 2021;36(9):1616\u201328.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"4561_CR28","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/ASN.2020081150","volume":"32","author":"S Fishbane","year":"2021","unstructured":"Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. J Am Soc Nephrol. 2021;32(3):737\u201355.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"4561_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jfma.2021.06.004","volume":"121","author":"YP Hou","year":"2022","unstructured":"Hou YP, Mao XY, Wang C, Xu ZH, Bu ZH, Xu M, et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. J Formos Med Assoc. 2022;121(2):529\u201338.","journal-title":"J Formos Med Assoc"},{"issue":"9","key":"4561_CR30","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","volume":"36","author":"R Provenzano","year":"2021","unstructured":"Provenzano R, Shutov E, Eremeeva L, Korneyeva S, Poole L, Saha G, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transpl. 2021;36(9):1717\u201330.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4561_CR31","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1681\/ASN.2014111139","volume":"27","author":"L Holdstock","year":"2016","unstructured":"Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016;27(4):1234\u201344.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"4561_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000454818","volume":"45","author":"T Akizawa","year":"2017","unstructured":"Akizawa T, Tsubakihara Y, Nangaku M, Endo Y, Nakajima H, Kohno T, et al. Effects of Daprodustat, a novel hypoxia-inducible Factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol. 2017;45(2):127\u201335.","journal-title":"Am J Nephrol"},{"issue":"25","key":"4561_CR33","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","volume":"385","author":"AK Singh","year":"2021","unstructured":"Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, et al. Daprodustat for the treatment of Anemia in patients not undergoing dialysis. N Engl J Med. 2021;385(25):2313\u201324.","journal-title":"N Engl J Med"},{"issue":"25","key":"4561_CR34","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","volume":"385","author":"AK Singh","year":"2021","unstructured":"Singh AK, Carroll K, Perkovic V, Solomon S, Jha V, Johansen KL, et al. Daprodustat for the treatment of Anemia in patients undergoing dialysis. N Engl J Med. 2021;385(25):2325\u201335.","journal-title":"N Engl J Med"},{"issue":"5","key":"4561_CR35","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","volume":"90","author":"PE Pergola","year":"2016","unstructured":"Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH. Vadadustat, a novel oral hif stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016;90(5):1115\u201322.","journal-title":"Kidney Int"},{"issue":"5","key":"4561_CR36","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000464476","volume":"45","author":"ER Martin","year":"2017","unstructured":"Martin ER, Smith MT, Maroni BJ, Zuraw QC, DeGoma Em. Clinical trial of Vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol. 2017;45(5):380\u201388.","journal-title":"Am J Nephrol"},{"key":"4561_CR37","doi-asserted-by":"crossref","unstructured":"Nangaku M, Farag YMK, DeGoma E, Luo W, Vargo D, Khawaja Z. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized phase 2 trials in Japanese patients. Nephrol Dial Transpl. 2020.","DOI":"10.1093\/ndt\/gfaa060"},{"issue":"17","key":"4561_CR38","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","volume":"384","author":"GM Chertow","year":"2021","unstructured":"Chertow GM, Pergola PE, Farag YMK, Agarwal R, Arnold S, Bako G, et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med. 2021;384(17):1589\u2013600.","journal-title":"N Engl J Med"},{"issue":"17","key":"4561_CR39","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","volume":"384","author":"KU Eckardt","year":"2021","unstructured":"Eckardt KU, Agarwal R, Aswad A, Awad A, Block GA, Bacci MR, et al. Safety and efficacy of Vadadustat for anemia in patients undergoing dialysis. N Engl J Med. 2021;384(17):1601\u201312.","journal-title":"N Engl J Med"},{"issue":"7","key":"4561_CR40","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1681\/ASN.2020091311","volume":"32","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Kondo K, Kokado Y, Ueta K, Kaneko G, Tandai T, et al. Phase 3 randomized study comparing vadadustat with Darbepoetin Alfa for Anemia in Japanese patients with nondialysis-dependent CKD. J Am Soc Nephrol. 2021;32(7):1779\u201390.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"4561_CR41","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/ndt\/gfab055","volume":"36","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Kondo K, Ueta K, Kokado Y, Kaneko G, Matsuda H, et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrol Dial Transpl. 2021;36(9):1731\u201341.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"4561_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000500487","volume":"143","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Nangaku M, Yamaguchi T, Arai M, Koretomo R, Maeda K, et al. Enarodustat, conversion and maintenance therapy for Anemia in hemodialysis patients: a randomized, placebo-controlled phase 2b trial followed by long-term trial. Nephron. 2019;143(2):77\u201385.","journal-title":"Nephron"},{"issue":"7","key":"4561_CR43","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.ekir.2021.04.037","volume":"6","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Nangaku M, Yamaguchi T, Koretomo R, Maeda K, Miyazawa Y, et al. A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the symphony nd study. Kidney Int Rep. 2021;6(7):1840\u201349.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"4561_CR44","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1159\/000517053","volume":"7","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Nangaku M, Yamaguchi T, Koretomo R, Maeda K, Miyazawa Y, et al. A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: symphony hd study. Kidney Dis (Basel). 2021;7(6):494\u2013502.","journal-title":"Kidney Dis (Basel)"},{"issue":"1","key":"4561_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2215\/CJN.02510218","volume":"14","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T. Effects of Molidustat in the treatment of Anemia in CKD. Clin J Am Soc Nephrol. 2019;14(1):28\u201339.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"4561_CR46","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.ekir.2021.07.015","volume":"6","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Yamada T, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney Int Rep. 2021;6(10):2604\u201316.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"4561_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ckj\/sfy013","volume":"12","author":"L Holdstock","year":"2019","unstructured":"Holdstock L, Cizman B, Meadowcroft AM, Biswas N, Johnson BM, Jones D, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin Kidney J. 2019;12(1):129\u201338.","journal-title":"Clin Kidney J"},{"issue":"1","key":"4561_CR48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ckj\/sfy014","volume":"12","author":"AM Meadowcroft","year":"2019","unstructured":"Meadowcroft AM, Cizman B, Holdstock L, Biswas N, Johnson BM, Jones D, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J. 2019;12(1):139\u201348.","journal-title":"Clin Kidney J"},{"issue":"8","key":"4561_CR49","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2215\/CJN.16011219","volume":"15","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, et al. Efficacy and safety of daprodustat compared with Darbepoetin Alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clin J Am Soc Nephrol. 2020;15(8):1155\u201365.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4561_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000513103","volume":"52","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Hamano T, Akizawa T, Tsubakihara Y, Nagai R, Okuda N, et al. Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. Am J Nephrol. 2021;52(1):26\u201335.","journal-title":"Am J Nephrol"},{"issue":"10\u201311","key":"4561_CR51","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1159\/000518072","volume":"52","author":"H Yamamoto","year":"2021","unstructured":"Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T. Molidustat for renal anemia in nondialysis patients Previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. Am J Nephrol. 2021;52(10\u201311):884\u201393.","journal-title":"Am J Nephrol"},{"issue":"10\u201311","key":"4561_CR52","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1159\/000518071","volume":"52","author":"H Yamamoto","year":"2021","unstructured":"Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T. Efficacy and safety of molidustat for anemia in ESA-Naive nondialysis patients: a randomized, phase 3 trial. Am J Nephrol. 2021;52(10\u201311):871\u201383.","journal-title":"Am J Nephrol"},{"issue":"6","key":"4561_CR53","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1159\/000500232","volume":"49","author":"DV Parmar","year":"2019","unstructured":"Parmar DV, Kansagra KA, Patel JC, Joshi SN, Sharma NS, Shelat AD, et al. Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study. Am J Nephrol. 2019;49(6):470\u201378.","journal-title":"Am J Nephrol"},{"issue":"5","key":"4561_CR54","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000523961","volume":"53","author":"D Agrawal","year":"2022","unstructured":"Agrawal D, Varade D, Shah H, Nazar A, Krishnan J, Shukla V, et al. Desidustat in anemia due to non-dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-ND). Am J Nephrol. 2022;53(5):352\u201360.","journal-title":"Am J Nephrol"},{"issue":"5","key":"4561_CR55","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000523949","volume":"53","author":"S Gang","year":"2022","unstructured":"Gang S, Khetan P, Varade D, Chinta VR, Mavani S, Gupta U, et al. Desidustat in anemia due to dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-D). Am J Nephrol. 2022;53(5):343\u201351.","journal-title":"Am J Nephrol"},{"issue":"6","key":"4561_CR56","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/jamainternmed.2022.0605","volume":"182","author":"AK Singh","year":"2022","unstructured":"Singh AK, Cizman B, Carroll K, McMurray JJV, Perkovic V, Jha V, et al. Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: a randomized clinical trial. JAMA Intern Med. 2022;182(6):592\u2013602.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"4561_CR57","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000502012","volume":"143","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Macdougall IC, Berns JS, Yamamoto H, Taguchi M, Iekushi K, et al. Iron regulation by Molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron. 2019;143(4):243\u201354.","journal-title":"Nephron"},{"issue":"7","key":"4561_CR58","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","volume":"6","author":"C Charytan","year":"2021","unstructured":"Charytan C, Manllo-Karim R, Martin ER, Steer D, Bernardo M, Dua SL, et al. A randomized trial of roxadustat in anemia of kidney failure: sierras study. Kidney Int Rep. 2021;6(7):1829\u201339.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"4561_CR59","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","volume":"6","author":"DW Coyne","year":"2021","unstructured":"Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2021;6(3):624\u201335.","journal-title":"Kidney Int Rep"},{"issue":"10","key":"4561_CR60","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","volume":"38","author":"B Csiky","year":"2021","unstructured":"Csiky B, Sch\u00f6mig M, Esposito C, Barratt J, Reusch M, Valluri U, et al. Roxadustat for the maintenance treatment of Anemia in patients with end-Stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Adv Ther. 2021;38(10):5361\u201380.","journal-title":"Adv Ther"},{"issue":"9","key":"4561_CR61","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","volume":"36","author":"E Shutov","year":"2021","unstructured":"Shutov E, Su\u0142owicz W, Esposito C, Tataradze A, Andric B, Reusch M, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transpl. 2021;36(9):1629\u201339.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"4561_CR62","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","volume":"67","author":"RA Brigandi","year":"2016","unstructured":"Brigandi RA, Johnson B, Oei C, Westerman M, Olbina G, de Zoysa J, et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial. Am J Kidney Dis. 2016;67(6):861\u201371.","journal-title":"Am J Kidney Dis"},{"key":"4561_CR63","doi-asserted-by":"crossref","unstructured":"Bailey CK, Caltabiano S, Cobitz AR, Huang C, Mahar KM, Patel VV. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis. BMC Nephrol. 2019;20(1):372.","DOI":"10.1186\/s12882-019-1547-z"},{"issue":"4","key":"4561_CR64","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000499111","volume":"49","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Macdougall IC, Berns JS, Bernhardt T, Staedtler G, Taguchi M, et al. Long-term efficacy and safety of molidustat for anemia in chronic kidney disease: dialogue extension studies. Am J Nephrol. 2019;49(4):271\u201380.","journal-title":"Am J Nephrol"},{"issue":"1","key":"4561_CR65","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","volume":"6","author":"L Mbuagbaw","year":"2017","unstructured":"Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Rev. 2017;6(1):79.","journal-title":"Systematic Rev"},{"issue":"5","key":"4561_CR66","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/aje\/kwab278","volume":"191","author":"G Salanti","year":"2022","unstructured":"Salanti G, Nikolakopoulou A, Efthimiou O, Mavridis D, Egger M, White IR. Introducing the treatment hierarchy question in network meta-analysis. Am J Epidemiol. 2022;191(5):930\u201338.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"4561_CR67","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/biomedicines9050468","volume":"9","author":"K Hirota","year":"2021","unstructured":"Hirota K. HIF-\u03b1 prolyl hydroxylase inhibitors and their implications for biomedicine: a comprehensive review. Biomedicines. 2021;9(5):468.","journal-title":"Biomedicines"},{"issue":"3","key":"4561_CR68","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MOH.0000000000000494","volume":"26","author":"C Renassia","year":"2019","unstructured":"Renassia C, Peyssonnaux C. New insights into the links between hypoxia and iron homeostasis. Curr Opin Hematol. 2019;26(3):125\u201330.","journal-title":"Curr Opin Hematol"},{"issue":"10","key":"4561_CR69","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.3390\/jcm11102722","volume":"11","author":"H Fadlalmola","year":"2022","unstructured":"Fadlalmola H, Al-Sayaghi K, Al-Hebshi A, Aljohani M, Albalawi M, Kashari O, et al. Efficacy of different doses of Daprodustat for anemic non-dialysis patients with chronic kidney disease: a systematic review and network meta-analysis. J Clin Med. 2022;11(10):2722.","journal-title":"J Clin Med"},{"key":"4561_CR70","doi-asserted-by":"publisher","first-page":"1131516","DOI":"10.3389\/fendo.2023.1131516","volume":"14","author":"J Yang","year":"2023","unstructured":"Yang J, Xing J, Zhu X, Xie X, Wang L, Zhang X. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: a network meta-analysis. Front Endocrinol (Lausanne). 2023;14:1131516.","journal-title":"Front Endocrinol (lausanne)"},{"issue":"4","key":"4561_CR71","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","volume":"26","author":"NS Sanghani","year":"2019","unstructured":"Sanghani NS, Haase VH. Hypoxia-inducible factor activators in renal anemia: current clinical experience. Adv Chronic Kidney Dis. 2019;26(4):253\u201366.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"11","key":"4561_CR72","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/jcph.1648","volume":"60","author":"R Provenzano","year":"2020","unstructured":"Provenzano R, Tumlin J, Zabaneh R, Chou J, Hemmerich S, Neff TB, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for treatment of anemia in chronic kidney disease: a placebo-controlled study of pharmacokinetic and pharmacodynamic profiles in hemodialysis patients. J Clin Pharmacol. 2020;60(11):1432\u201340.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"4561_CR73","doi-asserted-by":"publisher","first-page":"sfae051","DOI":"10.1093\/ckj\/sfae051","volume":"17","author":"T Nakanishi","year":"2024","unstructured":"Nakanishi T, Kuragano T. Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia. Clin Kidney J. 2024;17(3):sfae051.","journal-title":"Clin Kidney J"},{"issue":"14","key":"4561_CR74","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3390\/cells14141121","volume":"14","author":"T G\u00e1ll","year":"2025","unstructured":"G\u00e1ll T, Peth\u0151 D, Nagy A, P\u00f3liska S, Balla G, Balla J. Prolyl hydroxylase inhibitor-mediated hif activation drives transcriptional reprogramming in retinal pigment epithelium: relevance to chronic kidney disease. Cells. 2025;14(14):1121.","journal-title":"Cells"},{"issue":"1","key":"4561_CR75","doi-asserted-by":"publisher","first-page":"2195011","DOI":"10.1080\/0886022X.2023.2195011","volume":"45","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Mao M, Li J, Deng F. The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2023;45(1):2195011.","journal-title":"Ren Fail"},{"key":"4561_CR76","doi-asserted-by":"publisher","first-page":"780206","DOI":"10.3389\/fphys.2021.780206","volume":"12","author":"SV Ochoa","year":"2021","unstructured":"Ochoa SV, Otero L, Aristizabal-Pachon AF, Hinostroza F, Carvacho I, Torres YP. Hypoxic regulation of the large-conductance, calcium and voltage-activated potassium Channel, BK. Front Physiol. 2021;12:780206.","journal-title":"Front Physiol"},{"key":"4561_CR77","doi-asserted-by":"publisher","first-page":"1163908","DOI":"10.3389\/fphar.2023.1163908","volume":"14","author":"D Chen","year":"2023","unstructured":"Chen D, Niu Y, Liu F, Yang Y, Wang X, Li P, et al. Safety of hif prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis. Front Pharmacol. 2023;14:1163908.","journal-title":"Front Pharmacol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04561-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04561-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04561-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:01:19Z","timestamp":1781614879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04561-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4561"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04561-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human participants, human data, or human tissue. Therefore, ethical approval and consent to participate were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"638"}}